| Array BioPharma, Inc. (ARRY)
| "Array BioPharma, Inc." Graph source Edgar Online Pro on April 21st, 2006
The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 10-K for Fiscal Year Ended JUNE 30, 2005 The overview of the company was:
Array BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs to treat debilitating and life-threatening diseases. The company’s drug development pipeline primarily focuses on the treatment of cancer and inflammatory disease, and includes drugs that regulate targets in therapeutically important disease pathways. It offers ARRY-142886 (AZD6244)/MEK, which is in the Phase Ib clinical development, for the treatment of cancer. The company also provides ARRY-334543, ErbB-2/EGFR Inhibitors, and ErbB-2 Inhibitors that are in preclinical models of human cancer. It has collaborations with Amgen; AstraZeneca; Elan; Eli Lilly and Company; Genentech, Inc.; Hoffman-La Roche, Inc.; ICOS Corporation; InterMune, Inc.; Japan Tobacco, Inc.; Procter & Gamble Pharmaceuticals; QLT, Inc.; Ono Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company, Ltd. Array was founded in 1998 and is headquartered in Boulder, Colorado
Highlights of Risks Related to Our (ARRY) Business
For further detail please review the 10 K Form in detail.
Risks Related to Our (SPPI) Business:
1. We have a history of losses and may not achieve or sustain profitability.
2. Our drug candidates are at early stages of development, and we may not successfully develop a drug candidate that becomes a commercially viable drug.
3. Our business depends on the extent to which the pharmaceutical and biotechnology industries in-license drug candidates to fill their product pipelines and collaborate with other companies for one or more aspects of their drug discovery process.
4. We may not be successful in entering into additional out-license agreements on favorable terms.
5. We may not out-license our proprietary programs at the most appropriate time to maximize the total value or return of these programs to us.
6. Our collaborators have substantial control and discretion over the timing and the continued development and marketing of drug candidates we create.
7. The sale and manufacture of drug candidates that we develop with our collaborators or on our own may not receive regulatory approval.
8. Even if our drug candidates obtain regulatory approval, we and our collaborators will be subject to ongoing government regulation.
9. If our drug candidates do not gain market acceptance, we may be unable to generate significant revenue.
10. If we need but are unable to obtain additional funding to support our operations, we could experience a reduction in our ability to expand or be forced to reduce our operations.
11. We have limited clinical development and commercialization experience.
12. Our research and development capabilities may not produce viable drug candidates.
13. If our drug discovery and development programs do not progress as anticipated, our revenue and stock price could be negatively impacted.
14. We may not realize anticipated benefits from future acquisitions.
15. Because we rely on a small number of collaborators for a significant portion of our revenue, if one or more of our major collaborators terminates or reduces the scope of their agreement with us, our revenue may significantly decrease.
16. We may not be able to recruit and retain the experienced scientists and management we need to compete in the drug research and development industry.
17. We may not be able to meet the delivery and performance requirements set forth in our collaboration agreements.
18. Our quarterly operating results could fluctuate significantly.
19. We expect that revenue from our research tools will decline as a percentage of our total revenue in the future as we focus more resources on our proprietary research programs.
20. Our cGMP and pharmacology facilities and practices may fail to comply with government regulations.
21. Our development, testing and manufacture of drug candidates may expose us to product liability lawsuits.
22. If our use of chemical and hazardous materials violates applicable laws or regulations or causes personal injury we may be liable for damages.
23. Our operations could be interrupted by damage to our specialized laboratory facilities.
RISKS RELATED TO OUR INDUSTRY :
1. The concentration of the pharmaceutical and biotechnology industry and any further consolidation could reduce the number of our potential collaborators.
2. Capital market conditions may reduce our biotechnology collaborators’ ability to fund research.
3. Health care reform and cost control initiatives by third-party payors could reduce the prices that can be charged for drugs, which could limit the commercial success of our drug candidates.
4. We or our collaborators may not obtain favorable reimbursement rates for our drug candidates.
5. The drug research and development industry has a history of patent and other intellectual property litigation, and we may be involved in costly intellectual property lawsuits.
6. The intellectual property rights we rely on to protect our proprietary drug candidates and the technology underlying our tools and techniques may be inadequate to prevent third parties from using our technology or developing competing capabilities or to protect our interests in our proprietary drug candidates.
7. Agreements we have with our employees, consultants and collaborators may not afford adequate protection for our trade secrets, confidential information and other proprietary information.
8. The drug research and development industry is highly competitive, and we compete with some companies that offer a broader range of capabilities and have better access to resources than we do.
9. We face potential liability related to the privacy of health information we obtain from research institutions.
RISKS RELATED TO OUR STOCK :
1. Our officers and directors have significant control over us and their interests may differ from those of our stockholders.
2. Because our stock price may be volatile, our stock price could experience substantial declines.
3. Because we do not intend to pay dividends, stockholders will benefit from an investment in our common stock only if it appreciates in value.
4. The ability of our stockholders to control our policies and effect a change of control of our company is limited, which may not be in the best interests of our stockholders.
Recent articles on the medical industry:
For New Research Projects Contact The Chairman at Email: firstname.lastname@example.org
Disclaimer of Warranty and Limitation of Liability
products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.
The KIN Consortium does not warrant the information or services provided herein or your use of this
web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties,
including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose.
The KIN Consortium will not be responsible for any loss or damage that could result from interception
by third parties of any information or services made available to you via this web site. Although the information provided
to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium
cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available
to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors,
officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage
that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any
other party involved in making this web site, the data contained herein or the products or services offered on this web site
available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these
materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN
Consortium or of any vendor providing software or services. In no event will The KIN Consortium
or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental
damages or any other damages of any kind even if The KIN Consortium or any other such party has been
advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any
viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone
or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator
errors, strikes or other labor problems. The KIN Consortium cannot and does not guarantee continuous,
uninterrupted or secure access to the web site.
All right, title and interest
in this web site and any content contained herein is the exclusive property of The KIN Consortium ,
except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and
you may print, copy and download any information or portion of this web site for your personal use only. You may not modify,
copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer,
or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products
or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior
written approval. If you copy or download any information or software from this web site, you agree that you will not remove
or obscure any copyright or other notices or legends contained in any such information.
The KIN Consortium and
other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium .
The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks
of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags
on other pages or sites on the World Wide Web without the written permission of The KIN Consortium
or such third party, which may own the marks.
Pursuant to Section 512(c)(2) of the Copyright Act, The KIN
Consortium designates the following agent to receive notifications of claimed infringement: Khalid I Natto,
The KIN Consortium , Email: email@example.com, Website: http://khalidnatto.tripod.com
Use of Links
This web site contains links
to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply
an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium
of any information contained in any third party web site. In no event shall The KIN Consortium be responsible
for the information contained on that site or your use of or inability to use such site. You should also be aware that the